to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective
: To evaluate that there is no different effect on HbA1c between routine lipid lowering
therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic
patients with impaired fasting glucose (IFG).
H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4
µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the
control drug (Pitavastatin 2 MG)
Phase:
Phase 4
Details
Lead Sponsor:
JW Pharmaceutical
Collaborators:
Ajou University School of Medicine Asan Medical Center Chonbuk National University Hospital Chonnam National University Hospital Chungnam National University Hospital Dong-A University Hospital Eulji University Hospital Gangnam Severance Hospital Hallym University Medical Center Hanllym University Medical Center Korea University Guro Hospital Korea University Guro Hospitla Kyunghee University Medical Center Samsung Medical Center Seoul National University Bundang Hospital Seoul National University Hospital Severance Hospital The Catholic Univ. of Korea Daejeon St. Marys Hostpial The Catholic University of Korea The Catholic University of Korea Uijeongbu St.Marys Hostpial The Catholic University of Korea Yeouido St.Marys Hostpial Ulsan University Hospital Yeungnam University Hospital Youngnam University Medical Center